R A Boyd
Overview
Explore the profile of R A Boyd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
447
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Byon W, Sweeney K, Frost C, Boyd R
CPT Pharmacometrics Syst Pharmacol
. 2017 May;
6(5):340-349.
PMID: 28547774
Apixaban is approved for treatment of venous thromboembolism (VTE) and prevention of recurrence. Population pharmacokinetics, pharmacokinetics-pharmacodynamics (anti-FXa activity), and exposure-response (binary bleeding and thromboembolic endpoints) of apixaban in VTE treatment...
2.
Boyd R, DiCarlo L, Mandema J
Clin Transl Sci
. 2017 May;
10(4):260-270.
PMID: 28467656
We carried out a dose-response model-based meta-analysis to assess venous thromboembolism (VTE) and bleeding with factor Xa (FXa) inhibitors (apixaban, edoxaban, rivaroxaban) and a thrombin inhibitor (dabigatran) compared with European...
3.
Cohen A, Boyd R, Mandema J, DiCarlo L, Pak R
J Thromb Haemost
. 2013 Jun;
11(8):1503-10.
PMID: 23782955
Background: PD 0348292 is an oral, selective, direct and reversible factor Xa inhibitor. This was an adaptive dose-ranging study evaluating a 100-fold PD 0348292 dose range in subjects undergoing total...
4.
Milligan P, Brown M, Marchant B, Martin S, van der Graaf P, Benson N, et al.
Clin Pharmacol Ther
. 2013 Apr;
93(6):502-14.
PMID: 23588322
The pharmaceutical industry continues to face significant challenges. Very few compounds that enter development reach the marketplace, and the investment required for each success can surpass $1.8 billion. Despite attempts...
5.
Mandema J, Gibbs M, Boyd R, Wada D, Pfister M
Clin Pharmacol Ther
. 2011 Nov;
90(6):766-9.
PMID: 22089340
High development cost, low development success, cost-disciplined health-care policies, and intense competition demand an efficient drug development process. New compounds need to bring value to patients by being safe, efficacious,...
6.
Mandema J, Boyd R, DiCarlo L
Clin Pharmacol Ther
. 2011 Nov;
90(6):820-7.
PMID: 22048231
Information on the comparative effectiveness of drugs is crucial for drug development decisions, in addition to being needed by regulators, prescribers, and payers. We have carried out a dose-response meta-analysis...
7.
Boyd R, Lalonde R
Clin Pharmacol Ther
. 2006 Dec;
81(1):24-6.
PMID: 17185993
Much has been written recently about low productivity in the pharmaceutical industry and the high cost of drug development. Over a 10-year period ending in 2000, only approximately 11% of...
8.
Boyd R, Hogstrom K, White R, Starkschall G
Phys Med Biol
. 2001 Nov;
46(11):2841-56.
PMID: 11720350
The electron pencil-beam redefinition algorithm (PBRA), which is used to calculate electron beam dose distributions, assumes that the virtual source of each pencil beam is identical to that of the...
9.
Boyd R, Hogstrom K, Starkschall G
Med Phys
. 2001 Nov;
28(10):2096-104.
PMID: 11695771
The electron pencil-beam redefinition algorithm (PBRA) is currently being refined and evaluated for clinical use. The purpose of this work was to evaluate the accuracy of PBRA-calculated dose in the...
10.
Spicer S, Ha H, Boyd R, He X, Carter N, Tran G, et al.
J Immunol
. 2001 Sep;
167(7):3725-33.
PMID: 11564788
The role of IL-4, a key Th2 cytokine, in promoting or inhibiting active Heymann nephritis (HN) was examined. HN is induced by immunization with Fx1A in CFA, and proteinuria in...